BATM Advanced Communications Ld Major new customer for COVID-19 diagnostic tests
RNS Number : 0233B
BATM Advanced Communications Ld
05 October 2020
5 October 2020
BATM Advanced Communications Limited
("BATM" or "the Group")
BATM receives initial EUR4.3m order from major lab for COVID-19
New significant customer order for Real-Time PCR test kits and
instruments to be delivered this year
BATM (LSE: BVC; TASE: BVC), a leading provider of real-time
technologies for networking solutions and medical laboratory
systems, is delighted to announce that it has received an initial
EUR4.3m order for its COVID-19 Real-Time PCR diagnostic test kits
and instruments. The order is from a major new customer and is to
be delivered during Q4. The Group also provides an update on its
new diagnostic tests being developed for respiratory diseases.
The new customer is a significant global private laboratory
group headquartered in Italy that provides COVID-19 testing
throughout Europe, primarily for large businesses such as airports.
The order is for the Group's Real-Time PCR (antigen) test that
diagnoses whether an individual is currently infected with
SARS-CoV-2, the virus that causes the disease Coronavirus 2019
(COVID-19). The customer has also purchased, as part of the same
order, the Group's Ampilab qPCR and Extralab extractor instruments.
BATM expects to receive further significant orders from this
customer during Q4 and over the next 12 months.
The Group's Ampilab 6 band qPCR instrument can run all standard
test kits, but also advanced 5 (4+1) gene kits, such as the Group's
newest COVID-19 antigen kit, with great speed and accuracy. As a
result, it is a very cost efficient solution for labs.
In addition, the Group is pleased to provide the following
progress updates on its new testing kits:
-- The Group has started to deliver its COVID-19 antigen kit
that was upgraded to detect the spike (S) protein, as announced on
15 July 2020. By being able to detect the S gene, this test can
provide more accurate results by identifying the virus even in
those with a low viral load, which is important in preventing non-
and pre-symptomatic individuals from unknowingly spreading the
-- The new multi pathogen respiratory kit, also announced on 15
July 2020, is in the final validation phase and production and
deliveries are expected to commence during Q4.
-- Production is commencing of the Group's jointly-developed
home test kit for flu after being CE certified and validated.
-- The Group is making strong progress with the
jointly-developed COVID-19 home test kit, which is at an advanced
Dr Zvi Marom, Chief Executive Officer of BATM, said: "We are
pleased to have received this order from a new significant customer
for our COVID-19 test kits and diagnostic instruments. The
substantial interest in these solutions is growing as the pandemic
prevails throughout much of the world and we head towards flu
season. We believe that we will receive further sizeable orders
from our existing customers as well as continue to gain new
customers for these products.
"We are also delighted with the progress that we have made with
our newly-developed tests for COVID-19, flu and other respiratory
disease. Thanks to our innovative diagnostic platform, we can offer
a high-quality comprehensive solution to help protect public health
in the current pandemic and beyond."
BATM Advanced Communications
Dr Zvi Marom, Chief Executive Officer +972 9866 2525
Moti Nagar, Chief Financial Officer
Mark Percy, Anita Ghanekar, James Thomas (Corporate Advisory)
Henry Willcocks (Corporate Broking) +44 20 7408 4050
Harry Chathli, Claire Norbury +44 20 7618 9100
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact firstname.lastname@example.org or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
(END) Dow Jones Newswires
October 05, 2020 02:00 ET (06:00 GMT)